Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

In phase 2 study, idecabtagene vicleucel, a B-cell maturation antigen–directed CAR T-cell therapy, induced responses in majority of heavily pretreated patients, with 94 of 128 patients (73%) having a response to treatment, and almost all patients had grade 3 or 4 toxic effects.

Source:

New England Journal of Medicine